Acromegaly - Market Insight, Epidemiology And Market Forecast - 2032

This ‘Acromegaly - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of Acromegaly historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.

The Acromegaly market report provides current treatment practices, emerging drugs, market share of individual therapies, and the current and forecasted 7MM Acromegaly market size. The report also covers the Acromegaly procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the UK
• Japan

Study Period: 2019-2032

Acromegaly Understanding

Acromegaly Overview

Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. These hormones regulate many different bodily functions. In most patients, acromegaly is caused by the growth of a benign tumor (adenoma) arising from the pituitary gland. Symptoms of acromegaly include abnormal enlargement in the hands, arms, feet, legs, and head bones. Enlargement of the bones in the jaws and the front of the skull are typically the most apparent bony changes.

Signs and Symptoms of Acromegaly

Common signs and symptoms of acromegaly are enlarged hands and feet. For example, patients cannot put on rings that used to fit, and the shoe size has progressively increased. It may also cause gradual changes in the face shape, such as a protruding lower jaw and brow bone, an enlarged nose, thickened lips, and wider spacing between the teeth. Because acromegaly progresses slowly, early signs may not be obvious for years. Sometimes, people notice the physical changes only by comparing old photos with newer ones. Overall, acromegaly signs and symptoms tend to vary from one person to another and may include any of the following: enlarged hands and feet, enlarged facial features, including the facial bones, lips, nose, and tongue, coarse, oily, thickened skin, excessive sweating, and body odor.

Causes of Acromegaly

Acromegaly is a rare disorder caused by excess levels of growth hormone (GH) in the body. In most patients, excess levels of GH are caused by a benign (noncancerous) tumor in the pituitary gland (pituitary adenoma). Most adenomas form from the excessive growth of a pituitary cell called a somatotrope cell (the pituitary cell that normally secretes GH). In most patients, the disease is sporadic and not due to an inherited genetic mutation.

Biomarkers of Acromegaly

The best biomarker currently used in Pituitary Adenomas is the Ki-67 nuclear labeling index. It is expressed throughout the cell cycle and routinely detected using the MIB-1 monoclonal antibody. This assay is useful but not perfectly reliable. p53, a cellular tumor antigen involved in cell cycle regulation, has also been used as a possible biomarker for identifying pituitary adenomas.

Acromegaly Epidemiology

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Acromegaly, Tumor Origin-specific Cases of Acromegaly, Gender-specific Cases of Acromegaly, Tumor Size-specific Cases of Acromegaly covering the United States, EU4 (Germany, France, Italy, Spain), UK and Japan from 2019 to 2032.

Key Findings

• In 2022, the total diagnosed prevalent cases of Acromegaly in the United States were ~27,000 cases, which are anticipated to increase by 2032.
• EU4 and the UK accounted for ~21,000 diagnosed prevalent cases of Acromegaly in 2022, which is anticipated to increase by 2032.
• In Japan, tumor origin-specific cases of Acromegaly were ~9,100 and ~480 for pituitary and non-pituitary tumors, respectively, in 2022, which are likely to increase by 2032.
• In EU4 and the UK, tumor size-specific cases of acromegaly were ~18,300 and ~3,050 for macroadenomas and microadenomas, respectively, in 2022, which are likely to increase by 2032.

Acromegaly Drug Chapters

Acromegaly Marketed Drugs

MYCAPSSA (octreotide acetate): Amryt Pharma/Chiasma

MYCAPSSA is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It reduces the production of GH by binding to receptors on specialized cells in the pituitary gland. Being administrated orally, these capsules can serve as an alternative to the current standard-of-care injection therapy available for people living with acromegaly today.

SIGNIFOR LAR (pasireotide): Recordati/Novartis Pharmaceuticals

Novartis Pharmaceuticals developed SIGNIFOR LAR (pasireotide) as an injectable suspension. It is a long-acting release form of pasireotide pamoate, as a powder to be suspended in the provided diluent immediately before intramuscular injection. SIGNIFOR LAR is a somatostatin analog that consists of pasireotide pamoate uniformly distributed within microspheres which are made of biodegradable copolymers of poly (D, L-lactide-co-glycolide) acids (PLGA), and it is available in a vial containing the sterile pasireotide pamoate.

Acromegaly Emerging Drugs

Paltusotine (CRN 00808): Crinetics Pharmaceuticals

Paltusotine (CRN 00808), developed by Crinetics Pharmaceuticals, is an oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist with potential growth hormone (GH) secretion-inhibiting and antineoplastic activities. It is designed to reduce excess GH secretion from benign pituitary tumors and normalize IGF-1 levels in patients with acromegaly.

CAM-2029 (octreotide subcutaneous depot): Camurus AB

CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus' proprietary Fluid Crystal injection depot technology. It is provided as a prefilled syringe, thus not requiring reconstitution or conditioning before administration. Due to the superior ease of handling and administration, CAM2029 can conveniently be administered by patients. It was developed for the treatment of acromegaly and neuroendocrine tumors. This drug offers the potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.

Acromegaly Market Outlook

Acromegaly can start at any time after puberty. However, it occurs more often in middle age, and people are not always aware of their condition. Changes to the body may take place slowly over many years. Although acromegaly is treatable in most people, as symptoms gradually develop, health problems can develop before the disorder is diagnosed and treated.

The current treatment options include surgery, medicines, and radiation therapy. The treatment goals are to control tumor size, return GH and IGF-I levels to normal, improve symptoms, and manage related health problems. Currently, three types (Somatostatin analogs, dopamine agonists, and growth hormone-receptor antagonists) of medicines are used to treat acromegaly. However, they do not provide a cure for the disease. The medicines may be used alone or in combination with each other. The third treatment option is radiation therapy (stereotactic and conventional), which uses high-energy x-rays or particle waves to kill tumor cells. This type of treatment may be recommended if surgery is impossible or fails to remove all tumor tissue, and medicines are not an option.

However, in the current scenario, the treatment method for acromegaly is focused on preventing the tumor compression of surrounding tissues by excising the diseases causing areas and on reducing GH and IGF-1 levels to normal. Although the primary treatment method for acromegaly is transsphenoidal surgery, not all patients are eligible for surgery. Patients diagnosed with microadenomas and those with macroadenomas not close to other key structures in the brain, such as the nerves supplying the eyes or nearby blood vessels, are recommended for surgery.

Key Findings

• In 2022, the United States had the largest Acromegaly market size of ~USD 700 million among the 7MM countries.
• Among the EU4 countries, Germany had the largest market size for Acromegaly in 2022, i.e., ~USD 90 million.
• The smallest market size among EU4 countries was estimated in Spain, with ~USD 50 million in 2022.
• The market size of Acromegaly in the UK was found to be ~USD 110 million in 2022.

The United States Market Outlook

This section provides the total Acromegaly market size and market size by therapies in the United States.

EU4 and the UK Market Outlook

The total Acromegaly market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Acromegaly market size and market size by therapies in Japan are provided.

Acromegaly Drugs Uptake

This section focuses on the uptake rate of potential drugs recently launched in the Acromegaly market or expected to get launched in the market during the study period 2019-2032. The analysis covers the Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acromegaly Development Activities

The report provides insights into therapeutic candidates in Phase II and III stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for Acromegaly emerging therapies.

Reimbursement Scenario in Acromegaly

Approaching reimbursement proactively can positively impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

The publisher performs competitive market Intelligence analysis of the Acromegaly market using various competitive intelligence tools, including SWOT analysis, market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of Acromegaly, explaining its procedure, causes, clinical manifestations, and currently available therapies.
• Comprehensive insight has been provided into Acromegaly epidemiology and treatment.
• Additionally, an all-inclusive account of the current and emerging therapies for Acromegaly is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• The report includes a detailed review of the historical and forecasted Acromegaly market, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Acromegaly market.

Report Highlights

• The pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Acromegaly market.
• Companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development focus on novel approaches to treat/improve the disease condition using Acromegaly.

Major players are involved in developing therapies for Acromegaly. The launch of emerging therapies will significantly impact the Acromegaly market.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Acromegaly Report Insights

• Patient Population
• Therapeutic Approaches
• Acromegaly Pipeline Analysis
• Acromegaly Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Acromegaly Report Key Strengths

• 10-Year Forecast
• The US, EU4 and the UK, and Japan Coverage
• Acromegaly Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Acromegaly Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT analysis
• Key Questions

Market Insights:

• What was the Acromegaly market share (%) distribution in 2019, and what would it look like in 2032?
• What would be the Acromegaly total market size as well as market size by therapies across the 7MM during the forecast period (2023-2032)?
• What are the key findings pertaining to the market across the 7MM Coverage, and which country will have the largest Acromegaly market size during the forecast period (2023-2032)?
• At what CAGR the Acromegaly market is expected to grow at the 7MM Coverage level during the forecast period (2023-2032)?
• What would be the Acromegaly market outlook across the 7MM Coverage during the forecast period (2023-2032)?
• What would be the Acromegaly market growth till 2032, and what would be the resultant market size in 2032?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the risk, burdens, and unmet needs of Acromegaly?
• What is the historical Acromegaly patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient pool of Acromegaly at the 7MM Coverage level?
• What will be the growth opportunities across the 7MM Coverage with respect to the patient population pertaining to Acromegaly?
• Out of the above-mentioned countries, which country would have the highest cases of Acromegaly during the forecast period (2023-2032)?
• At what CAGR are these cases expected to grow across the 7MM Coverage during the forecast period (2023-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current treatment practices in Acromegaly, along with the approved therapy?
• What are the current treatment guidelines for Acromegaly?
• What are the Acromegaly marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for Acromegaly?
• How many emerging therapies are in the mid-stage and late stages of development for Acromegaly?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Acromegaly therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acromegaly and their status?
• What key designations have been granted for the emerging therapies for Acromegaly?
• What is the 7MM Coverage historical and forecasted market of Acromegaly?

Reasons to Buy

• The report will help develop business strategies by understanding trends shaping and driving Acromegaly.
• To understand the future market competition in the Acromegaly market and an insightful review of the market.
• Organize sales and marketing efforts by identifying the best opportunities for Acromegaly in the 7MM Coverage.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Acromegaly market.
• To understand the future market competition in the Acromegaly market.